Danuil Julián Melo Ascanio

Danuil Julián Melo Ascanio

Auto-generated profile, based on publicly available information

Danuil Julián Melo Ascanio

Universidad Metropolitana

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2024 in Ciencia Latina Revista Científica Multidisciplinar
Verified
Journal Article
Open access
PDF file
YNYurley Daniela Duarte Nariño
Yurley Daniela Duarte Nariño
MOMaria Lucia Vega Olarte
Maria Lucia Vega Olarte
CPCarlos Javier Navarro Peñaranda
Carlos Javier Navarro Peñaranda
JMJosé Andrés González Martínez
José Andrés González Martínez
MSMaroly Andrea Duarte Solano
Maroly Andrea Duarte Solano
DADanuil Julián Melo Ascanio
Danuil Julián Melo Ascanio
La miocardiopatía periparto (MCPP) es una causa rara de miocardiopatía que ocurre durante la última etapa del embarazo o en el período posparto temprano. Se caracteriza por una disfunción significativa del ventrículo izquierdo e insuficiencia cardíaca en el período periparto que ocurre en ausencia de otras causas identificables de insuficiencia cardíaca. La fracción de eyección del ventrículo izquierdo casi siempre es inferior al 45 por ciento, y el ventrículo izquierdo puede estar dilatado o no. Esta actividad describe la evaluación, el diagnóstico y el tratamiento de la miocardiopatía periparto y destaca el papel de la atención interprofesional en equipo para las pacientes afectadas.

15 September 2026 in Health Care & Global Health
Verified
Journal Article
Open access
PDF file
DMDanuil Julián Melo-Ascanio
Danuil Julián Melo-Ascanio
MPMaria Alejandra Palacios-Rodríguez
Maria Alejandra Palacios-Rodríguez
LMLesly Giovanna Maldonado-Burbano
Lesly Giovanna Maldonado-Burbano
JAJuan Camilo Arias-Pérez
Juan Camilo Arias-Pérez
VBValentina Bravo-Echeverry
Valentina Bravo-Echeverry
ACAntonio José Carvajal-Mazuera
Antonio José Carvajal-Mazuera
Type 2 diabetes mellitus (T2DM) poses increasing perioperative challenges due to the widespread use of modern antidiabetic therapies with cardiometabolic, renal, and weight-related benefits, but also specific anesthetic and metabolic safety implications. This narrative review integrated clinical, pharmacological, and perioperative evidence on glucagon-like peptide-1 receptor agonists (GLP-1RA), dual GIP/GLP-1 agonists, and sodium-glucose cotransporter-2 inhibitors (SGLT2i). GLP-1RA and dual GIP/GLP-1 agonists are associated with delayed gastric emptying and increased residual gastric content, although their relationship with clinically significant pulmonary aspiration remains uncertain. Gastric ultrasound may support individualized risk stratification in selected settings. Conversely, SGLT2i are linked to euglycemic diabetic ketoacidosis, particularly during fasting, surgery, infection, dehydration, or carbohydrate restriction, requiring preoperative discontinuation, metabolic surveillance, and delayed reinitiation until clinical stability, euvolemia, and oral tolerance are achieved. Perioperative care in T2DM should move beyond a glucose-centered approach and incorporate medication reconciliation, multidisciplinary assessment, and individualized decision-making based on anesthetic, metabolic, and surgical risk. Keywords: Diabetes Mellitus, Type 2; Perioperative Care; Glucagon-Like Peptide-1 Receptor Agonists; Sodium-Glucose Transporter 2 Inhibitors; Diabetic Ketoacidosis (Source: MeSH, NLM).